as on February 18, 2026 at 7:59 am IST
Day's Low
Day's High
5.10%
Downside
1.09%
Upside
52 Week's Low
52 Week's High
38.10%
Downside
49.00%
Upside
Check Alnylam Pharmaceuticals, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$41.7B
EPS (TTM)
9.6984
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
134.94
Industry PE ratio
18.615128205128205
PEG Ratio
-0.49
EBITDA
557.2M
Revenue (TTM)
3.7B
Profit Margin
8.45%
Return On Equity TTM
73.28%
Track how Alnylam Pharmaceuticals, Inc. P/E has moved over time to understand its valuation trends.
Alnylam Pharmaceuticals, Inc. in the last 5 years
Lowest (-115.71x)
September 30, 2024
Industry (18.62x)
February 18, 2026
Today (134.94x)
February 18, 2026
Highest (166.89x)
September 30, 2025
Today’s Price to Earnings Ratio: 134.94x
Compare market cap, revenue, PE, and other key metrics of Alnylam Pharmaceuticals, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $41.7B | 121.4% | 134.94 | 8.45% | |
| BUY | $124.8B | 127.48% | 32.06 | 32.94% | |
| NA | $38.3B | NA | 665.52 | 1.38% | |
| BUY | $84.9B | 66.35% | 19.38 | 31.41% |
The Alnylam Pharmaceuticals, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Alnylam Pharmaceuticals, Inc. investment value today
Current value as on today
₹1,37,430
Returns
₹37,430
(+37.43%)
Returns from Alnylam Pharmaceuticals, Inc. Stock
₹33,036 (+33.04%)
Dollar Returns*
₹4,394 (+4.39%)
Based on 34 analysts
70.59%
Buy
29.41%
Hold
0.00%
Sell
Based on 34 analysts, 70.59% of analysts recommend a 'BUY' rating for Alnylam Pharmaceuticals, Inc.. Average target price of $459.4
Get share price movements and forecasts by analysts on Alnylam Pharmaceuticals, Inc..
What analysts predicted
27.6%UPSIDE
Target Price
$459.4
Current Price
$332.59
Analyzed by
34 Analysts
Target
$459.40
Alnylam Pharmaceuticals, Inc. target price $459.4, a slight upside of 27.6% compared to current price of $332.59. According to 34 analysts rating.
Search interest for Alnylam Pharmaceuticals, Inc. Stock has increased by 5% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:5% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 12 February
Thu, 06:43 PM
-Alnylam announces Q4 2025 financial results, reporting $1.1 billion in revenue, an 85% increase year-over-year.
Thu, 06:45 PM
-Alnylam Pharmaceuticals reports 2025 10-K, achieving profitability with total revenues of $3.7 billion, a 65% increase from 2024.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
![]()
In the last 7 days, ALNY stock has moved up by 3.2%
Against Peers
![]()
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 52.9% return, outperforming this stock by 3.6%
Against Peers
![]()
In the last 1 year, Beone Medicines Ltd has given 49.0% return, outperforming this stock by 16.0%
Revenue Fall
![]()
Alnylam Pharmaceuticals, Inc. has experienced a decline in revenue over the last two quarters. Their revenue fell from $1.24 billion to $1.09 billion, which represents an average decrease of 12.2% each quarter.
Profit Down
![]()
Alnylam Pharmaceuticals, Inc. has seen a decline in its net profit for the last two quarters. The net profit decreased from $251.08 million to $186.41 million, resulting in an average decrease of 25.8% per quarter.
| Organisation | Alnylam Pharmaceuticals, Inc. |
| Headquarters | 675 West Kendall Street, Cambridge, MA, United States, 02142 |
| Industry | Health Technology |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Pushkal P. Garg M.D. | Chief Research & Development Officer |
Mr. Timothy J. Maines | Chief Technical Operations & Quality Officer |
Mr. Piyush Sharma J.D. | Chief Ethics & Compliance Officer |
Mr. Bryan Andrew Supran J.D. | Chief Legal Officer |
Dr. Yvonne L. Greenstreet M.B.A., M.D. | CEO & Director |
Mr. Jeffrey V. Poulton M.B.A. | CFO & Executive VP |
Dr. Kevin Joseph Fitzgerald Ph.D. | Executive VP, Chief Scientific Officer and Head of Early Research & Early Development |
Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board |
Mr. Tolga Tanguler M.B.A. | Executive VP & Chief Commercial Officer |
Ms. Christine Regan Akinc | Chief Corporate Communications Officer |
Alnylam Pharmaceuticals, Inc. share price today is $332.59 as on at the close of the market. Alnylam Pharmaceuticals, Inc. share today touched a day high of $336.2 and a low of $315.62.
Alnylam Pharmaceuticals, Inc. share touched a 52 week high of $495.55 on and a 52 week low of $205.87 on . Alnylam Pharmaceuticals, Inc. stock price today i.e. is closed at $332.59,which is 32.88% down from its 52 week high and 61.55% up from its 52 week low.
Alnylam Pharmaceuticals, Inc. market capitalisation is $0.04T as on .
Indian investors can start investing in Alnylam Pharmaceuticals, Inc. (ALNY) shares with as little as ₹90.652 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹906.52 in Alnylam Pharmaceuticals, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Alnylam Pharmaceuticals, Inc. share’s latest price of $332.59 as on February 18, 2026 at 2:29 am IST, you will get 0.0301 shares of Alnylam Pharmaceuticals, Inc.. Learn more about
fractional shares .
Alnylam Pharmaceuticals, Inc. stock has given 121.4% share price returns and 24.64% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?